A Phase 3 interventional study of simvastatin (+) ezetimibe and Comparator: atorvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 32nd largest by enrollment of the 97 interventional ones that give a count, is one of 16 that started in 2007, is one of 50 in phase 3, and was the 27th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 16 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 43rd largest by enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2007, is one of 58 in phase 3, and was the 40th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea. Therefore this trial will help evaluate the lipid lowering effect of Vytorin® in asian population with metabolic syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
Drug: simvastatin (+) ezetimibe
atorvastatin 10 mg; tablet, once daily, 8 Weeks
Drug: Comparator: atorvastatin
Drug pages: Ezetimibe · Simvastatin
simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
Also known as: MK0653A, Vytorin®
atorvastatin 10 mg; tablet, once daily, 8 Weeks
Also known as: Lipitor®
Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.
Time frame: Baseline and 8 Weeks
Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.
Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment. LDL-C goal is based on National Cholesterol Education Program (NCEP) III guideline (LDL-C goals and cutpoints for therapeutic life changes and drug Therapy in different risk).
Time frame: Baseline and 8 weeks
Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.
Time frame: Baseline and Week 8
Patients were recruited between June 2007 and May 2008.
| Milestone | Vytorin | Atorvastatin |
|---|---|---|
| Started | 130 | 126 |
| Completed | 124 | 121 |
| Not completed | 6 | 5 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Percent of Baseline Value | Vytorin | Atorvastatin |
|---|---|---|
| Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks. | -49.29 ± 15.22 | -38.05 ± 12.28 |
Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment. LDL-C goal is based on National Cholesterol Education Program (NCEP) III guideline (LDL-C goals and cutpoints for therapeutic life changes and drug Therapy in different risk).
| Participants attaining LDL-C goal | Vytorin | Atorvastatin |
|---|---|---|
| Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment. | 105 | 93 |
| mg/dL | Vytorin | Atorvastatin |
|---|---|---|
| Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks. | 83.52 ± 33.84 | 98.27 ± 21.82 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vytorin | — | — | — |
| Atorvastatin | — | — | — |
| Event | Vytorin | Atorvastatin |
|---|---|---|
| Hepatic enzyme increasedInvestigations | 0/124 | 1/121 |
| PyrexiaGeneral disorders | 0/124 | 1/121 |
| DeathGeneral disorders | 1/124 | 0/121 |
| Event | Vytorin | Atorvastatin |
|---|---|---|
| HypercholesterolaemiaMetabolism and nutrition disorders | 6/124 | 6/121 |
| High Density lipoprotein decreasedInvestigations | 2/124 | 5/121 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 4/124 | 3/121 |
| Hepatic enzyme increasedInvestigations | 2/124 | 3/121 |
| Abdominal pain upperGastrointestinal disorders | 2/124 | 3/121 |
| HeadacheNervous system disorders | 2/124 | 3/121 |
| DizzinessNervous system disorders | 0/124 | 3/121 |
| Upper respiratory tract infectionInfections and infestations | 1/124 | 3/121 |
| DiarrhoeaGastrointestinal disorders | 0/124 | 2/121 |
| Blood Insulin IncreasedInvestigations | 2/124 | 0/121 |
| Age, Continuous(years) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 58.96 ± 9.42 | 60.26 ± 9.44 | 59.61 ± 9.44 |
| Sex: Female, Male(Participants) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Female | 36 | 43 | 79 |
| Male | 94 | 83 | 177 |
| Body Mass Index (BMI)(kg/m^2) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 26.75 ± 3.59 | 26.45 ± 3.34 | 26.61 ± 3.46 |
| Diastolic Blood Pressure(mm Hg) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 81.01 ± 8.47 | 82.11 ± 8.49 | 81.55 ± 8.48 |
| LDL-C (low-Density-Lipoprotein-Cholesterol)(mg/dL) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 159.95 ± 30.33 | 159.95 ± 27.34 | 159.95 ± 28.84 |
| Systolic Blood Pressure(mm Hg) | Vytorin | Atorvastatin | Total |
|---|---|---|---|
| Mean | 130.81 ± 13.91 | 129.85 ± 14.51 | 130.34 ± 14.19 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Simvastatin